Talk:New Article Requests

Before You Submit a Proposal

• EVALUATION CRITERIA: Review these to be sure your proposal is eligible.
• EXISTING ARTICLES: Review these to see if your proposed topic is already included or could be included in an existing EyeWiki article. You can do this by performing a thorough search using various related key terms.
  • If you find a pre-existing stand-alone article that addresses your topic or an article that includes your topic please edit the article to include your own input. You will be automatically recognized as a contributor to that article.
  • Of those proposals that are not accepted, 85% are rejected because the topic is already covered or could be covered in an existing EyeWiki article.
• PROPOSALS PREVIOUSLY SUBMITTED: Review these and please do not resubmit these topics.

Instructions

• IMPORTANT: Review the section above "Before You Submit a Proposal"
• Click the "Add topic" link to create a new proposal on this page
• Then add the relevant list items as shown
  • Title: Enter this in the Subject field
  • Summary: Please provide some details about what will be covered and why you think the article would benefit EyeWiki. Do not submit a complete article.
  • Section: Indicate what subspecialty section the article should be added to. You may indicate up to 2 sections.
  • Submitted by: Name of the ophthalmologist submitting the proposal. Sign and date your request by entering 4 tilde ~ characters only. This will automatically add your username, a time stamp and a link to your profile. You will see this after you save the page.
    • SAMPLE: Rayna.Ungersma.AAO (talk) 10:01, April 30, 2024 (PDT)
• Click: SAVE at the bottom of the page

Sample Proposal

Biosimilars in Ophthalmology
Summary: Patents for original biologics used to treat nAMD and DME are approaching expiration. Numerous companies are striving to replicate these biologics as biosimilars, which are drugs that mimic the effects of the original biologic, but do not have the same active ingredients. This article will summarize the current literature about biosimilars and their safety, efficacy, and quality and provide an in-depth review of approved biosimilars as well as those that are in development. This article will provide EyeWiki readers with information about numerous alternatives for treatment nAMD and DME.
Section: Retina/Vitreous
Submitted by: Rayna.Ungersma.AAO (talk) 15:04, May 1, 2024 (PDT)

Ocular Manifestations of Elder Abuse

Summary: Elder abuse is a growing yet underrecognized public health issue that can manifest with distinct ocular signs. Ophthalmologists may be the first to identify subtle or overt indicators of physical abuse in elderly patients. Common ocular manifestations include periorbital bruising, subconjunctival hemorrhages, eyelid lacerations, orbital fractures, and retinal hemorrhages, often without consistent trauma history. Chronic neglect may also present as untreated ocular surface disease, poor hygiene, or delayed care for vision-threatening conditions. Recognizing these signs in the context of behavioral cues, caregiver interactions, and inconsistent explanations is essential. Timely identification and appropriate reporting can play a critical role in safeguarding vulnerable elders.

Section: Ocular Trauma

Submitted by: Hashem.AbuSerhan (talk) 06:20, July 25, 2025 (PDT)

Local Anaesthetic-Induced Extraocular Myotoxicity

Summary: Local anaesthetic-induced extraocular myotoxicity is a rare but potentially debilitating complication of regional anaesthesia in ophthalmic surgery. It most commonly follows retrobulbar or peribulbar injection techniques. The pathophysiology involves direct myotoxic effects of local anaesthetics, particularly agents like bupivacaine and lidocaine, on extraocular muscle fibers—leading to muscle fiber necrosis, followed by inflammation and fibrosis. Clinically, patients may present with persistent diplopia, strabismus, or motility restriction, often involving the inferior rectus or lateral rectus muscles. Diagnosis is based on clinical suspicion, supported by imaging (e.g., MRI showing muscle enlargement or scarring). Management depends on severity and chronicity, ranging from conservative observation to strabismus surgery for persistent motility deficits. Awareness of this complication is essential to mitigate risks through careful technique, avoiding intramuscular injection, and using the lowest effective dose and concentration of anaesthetic agents.

Section: Neuro-ophthalmology/Orbit or/and Pediatric Ophthalmology/Strabismus

Submitted by: Hashem.AbuSerhan (talk) 10:52, July 25, 2025 (PDT)

Photobiomodulation in Retina Diseases

Summary: Photobiomodulation (PBM), also known as low-level light therapy (LLLT), is a non-invasive treatment modality that utilizes specific wavelengths of red and near-infrared light to stimulate mitochondrial activity and promote cellular function. Originally developed for wound healing and pain management, PBM has recently gained momentum in ophthalmology due to its potential therapeutic benefits in several retinal diseases. PBM works primarily by targeting cytochrome c oxidase in the mitochondrial respiratory chain, leading to increased ATP production, modulation of oxidative stress, and anti-inflammatory and neuroprotective effects. Treatment is administered using LED-based devices emitting light in the 590–850 nm range, typically delivered in multiple short sessions over several weeks. It is generally well tolerated and considered safe, with few contraindications. Clinical studies have shown promising results in dry age-related macular degeneration (AMD), with improvements in visual acuity and reduced progression of geographic atrophy. Evidence also suggests beneficial effects in diabetic retinopathy, retinitis pigmentosa, and central serous chorioretinopathy, primarily through mechanisms that address oxidative stress, inflammation, and vascular dysfunction. Moreover, in pathological myopia, PBM appears to slow axial elongation and refractive progression in children, offering a potential preventive strategy. While PBM is already FDA-approved for dry AMD, its broader clinical application is still under investigation. Ongoing research will clarify its role in retinal therapeutics and expand its potential indications. This article should be added to EyeWiki because it provides a comprehensive, evidence-based overview of photobiomodulation therapy and its emerging role in the management of retinal diseases, including recent clinical trial data and FDA approval.

Section: Retina

Submitted by:Rita.Martins (talk) 23:36, July 27, 2025 (PDT)